Korro Bio swaps 1M Venrock shares for pre-funded warrants, reports $137.9M cash and pipeline advances
KRRO has more than doubled off its 52-week low of $5.204.
Summary
Korro Bio exchanged 1 million Venrock common shares for pre-funded warrants, leaving the fully diluted share count unchanged. The company also reported Q2 2026 results with $137.9 million in cash and a runway into 2H 2028, alongside pipeline progress for KRRO-121 and KRRO-111.
Key Events · Financing and Capital Events · KRRO
-
Venrock Share-for-Warrant Exchange
Venrock surrendered 1,000,000 common shares for no consideration and received pre-funded warrants to purchase 1,000,000 shares at $0.001 per share, with no expiration. Post-exchange, outstanding shares drop to 13,725,646, but unexercised pre-funded warrants total 4,148,836, leaving fully diluted economics unchanged.
-
Q2 2026 Financial Results
Cash, cash equivalents, and marketable securities were $137.9 million as of June 30, 2026. Net loss was $18.9 million for the quarter, with R&D expenses of $13.6 million and G&A of $6.5 million. Cash runway extends into the second half of 2028.
-
KRRO-121 Regulatory Progress
KRRO-121 received EMA Orphan Drug Designation for urea cycle disorders and remains on track to commence a first-in-human clinical trial in the second half of 2026.
-
KRRO-111 Development Candidate Nomination
Korro nominated KRRO-111 as a development candidate for Alpha-1 Antitrypsin Deficiency (AATD), a GalNAc-conjugated oligonucleotide delivered subcutaneously, with preclinical data showing over 90% RNA editing and near-complete reduction of pathogenic Z-AAT protein.
Analysis · KRRO · Life Sciences
In a share-for-warrant exchange with Venrock, Korro Bio surrendered 1 million common shares and issued pre-funded warrants covering the same number of shares. While the outstanding share count drops by 1 million to 13.7 million, the warrants—exercisable at $0.001 with no expiration—preserve the same economic exposure. The net result is a cosmetic reduction in shares outstanding without altering Venrock's fully diluted stake. The filing also details Q2 2026 financials: $137.9 million in cash, a net loss of $18.9 million, and a cash runway into the second half of 2028. On the pipeline front, EMA Orphan Drug Designation for KRRO-121 and the nomination of KRRO-111 for AATD both signal positive momentum for the company's clinical trajectory.
At the time of this filing, KRRO was trading at $11.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $165.9M. The 52-week trading range was $5.20 to $55.89. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.